Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

TCGA-AO-A0J5-01A-11R-A034-07

— · A

ecc8eab8-af58-5ffb-b4ff-00a482c7876b

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
A
subtype
A
overall_survival_months
26

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.530
  • TGF_BETA_SIGNALING+0.490
  • UV_RESPONSE_DN+0.480
  • ANGIOGENESIS+0.440
  • APICAL_SURFACE+0.440
  • HEDGEHOG_SIGNALING+0.390
  • MYOGENESIS+0.380
  • APICAL_JUNCTION+0.330
  • CHOLESTEROL_HOMEOSTASIS+0.330
  • MITOTIC_SPINDLE+0.310

Top 10 suppressed

  • INTERFERON_ALPHA_RESPONSE-0.560
  • MYC_TARGETS_V2-0.500
  • MYC_TARGETS_V1-0.490
  • E2F_TARGETS-0.450
  • INTERFERON_GAMMA_RESPONSE-0.430
  • OXIDATIVE_PHOSPHORYLATION-0.370
  • DNA_REPAIR-0.350
  • ALLOGRAFT_REJECTION-0.320
  • REACTIVE_OXYGEN_SPECIES_PATHWAY-0.320
  • ESTROGEN_RESPONSE_LATE-0.300

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-A1-A0SH-01A-11R-A084-07
breast-umap@18
—A0.899
2SRR8518453
breast-umap@18
—F0.850
3TCGA-HD-7831-01A-11R-2132-07
head-neck@1
——0.816
434a7b3e9-caae-48d1-97a4-2bcb00fa2383
colon-landscapes@1
——0.815
5SRR8613703
breast-umap@18
—D0.813
6TCGA-D8-A146-01A-31R-A115-07
breast-umap@18
—A0.811
7SRR8613779
breast-umap@18
—D0.807
8MBCProject_0235_T1_RNA
breast-umap@18
—A0.806
9TCGA-BH-A1FH-01A-12R-A13Q-07
breast-umap@18
—A0.799
10TCGA-E9-A1NH-01A-11R-A14D-07
breast-umap@18
—A0.797

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 25 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
EPITHELIAL_MESENCHYMAL_TRANSITION0.530Inavolisib— uncovered
TGF_BETA_SIGNALING0.490Inavolisib— uncovered
UV_RESPONSE_DN0.480Inavolisib— uncovered
ANGIOGENESIS0.440Remibrutinib— uncovered
APICAL_SURFACE0.440Temsirolimus— uncovered
HEDGEHOG_SIGNALING0.390Inavolisib— uncovered
MYOGENESIS0.380Inavolisib— uncovered
APICAL_JUNCTION0.330Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.330Remibrutinib— uncovered
MITOTIC_SPINDLE0.310Inavolisib— uncovered
ANDROGEN_RESPONSE0.280Inavolisib— uncovered
PROTEIN_SECRETION0.270Remibrutinib— uncovered
COAGULATION0.220Binimetinib— uncovered
BILE_ACID_METABOLISM0.140Inavolisib— uncovered
NOTCH_SIGNALING0.130Inavolisib— uncovered
PANCREAS_BETA_CELLS0.130Cobimetinib— uncovered
HYPOXIA0.120Idelalisib— uncovered
APOPTOSIS0.110Idelalisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.110Inavolisib— uncovered
KRAS_SIGNALING_UP0.090Inavolisib— uncovered